Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed Formulation

NCT02283840 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
60
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Bial - Portela C S.A.